Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. Crescent’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com.
Our pipeline originated at Paragon Therapeutics, a biotechnology company founded by Fairmount. Crescent is the fifth company launched to advance assets discovered at Paragon.
Company Details
- Employees
- 36
- Address
- Associate Jobs
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.crescentbiopharma.com
- Keywords
- in multiple modalities.
Crescent Biopharma Questions
Crescent Biopharma's website is http://www.crescentbiopharma.com
Crescent Biopharma's LinkedIn profile is https://www.linkedin.com/company/crescent-biopharma
Crescent Biopharma has
36 employees.
View email and phone details for 36
employees at Crescent Biopharma.
Crescent Biopharma's industry is
Biotechnology Research
Crescent Biopharma's top competitors are
Monte Rosa Therapeutics,
Aerovate Therapeutics, Inc.,
Axonis Therapeutics,
Paragon Therapeutics, Inc.,
Evommune,
Ottimo Pharma,
Glycomimetics,
Jade Biosciences,
Kivu Bioscience,
Chimagen Biosciences.
Crescent Biopharma's categories are Biotechnology Research
